The Neuro Experience

How GLP-1s Reduce Alzheimer’s and Cancer Risk | ft. Dr. Rocio Salas-Whalen

25 snips
Oct 7, 2025
Dr. Rocio Salas-Whalen, a triple board-certified endocrinologist and obesity medicine expert, shares her insights on the groundbreaking GLP-1 therapies. She discusses how these medications can combat obesity, reduce inflammation, and potentially lower Alzheimer's and cancer risks. Dr. Salas-Whalen also explores the connection between estrogen, menopause, and weight gain, emphasizing a shift in patient goals from appearance to strength. Tune in for her take on the future of GLP-1 innovations and her upcoming book, 'Weightless.'
Ask episode
AI Snips
Chapters
Books
Transcript
Episode notes
ANECDOTE

Early Adoption Of GLP-1 Therapy

  • Dr. Salas-Whalen began using GLP-1s in 2010 after meeting a researcher and seeing dramatic glucose and weight benefits.
  • She started off-label prescribing for weight loss and watched patients lose weight and improve glucose control.
INSIGHT

GLP-1 Is A Widespread Gut Hormone

  • GLP-1 is a gut hormone released by L cells after eating and acts on receptors throughout the body.
  • Synthetic GLP-1 analogs are long-acting versions that avoid rapid DPP-4 breakdown and reach the brain and other organs.
INSIGHT

Drugs Quiet Food Reward Pathways

  • GLP-1 drugs reduce food-driven reward by acting on brain reward centers like the amygdala.
  • This reduces cravings and interrupts habitual reward-seeking eating behaviors.
Get the Snipd Podcast app to discover more snips from this episode
Get the app